R. Stupienski

Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499].

M. Sanguinetti, R. Stein, J. Lynch, 1994, The Journal of pharmacology and experimental therapeutics.

Cardiac electrophysiologic and antiarrhythmic actions of tedisamil.

J. Lynch, E. Baskin, S. D. Appleby, 1995, The Journal of pharmacology and experimental therapeutics.

Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction.

J. Lynch, G. Stump, A. Wallace, 1996, The Journal of pharmacology and experimental therapeutics.

Cardiac Electrophysiologic and Inotropic Actions of New and Potent Methanesulfonanilide Class III Antiarrhythmic Agents in Anesthetized Dogs

H. Selnick, J. Lynch, D. Claremon, 1991, Journal of cardiovascular pharmacology.

Antiarrhythmic actions of tocainide in canine models of previous myocardial infarction.

J. Lynch, L. Heaney, A. Wallace, 1991, American heart journal.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.

R. Gould, G. Hartman, N. Ihle, 1996, The Journal of pharmacology and experimental therapeutics.

Investigation of (Oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines.

D. Bindra, G. Rork, J. Cook, 1996, Journal of medicinal chemistry.

Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.

J. Lynch, J. Salata, N. Jurkiewicz, 1995, Circulation research.

Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.

R. Gould, G. Hartman, J. Lynch, 1997, Circulation.